High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.

BACKGROUND Infliximab (IFX) is effective in treating Crohn's disease (CD) and C-reactive protein (CRP) is a useful biomarker in assessing inflammatory activity. AIM Correlate CRP levels before beginning of IFX, at week 14 and CRP delta within the first year of IFX treatment. METHODS Retrospective study of CD patients undergoing treatment with IFX. Primary nonresponse (PNR) was defined as no symptomatic improvement and CRP persistently elevated; sustained response (SR) as symptomatic improvement for at least 1 year without therapeutic adjustment; response after therapeutic adjustment (RTA) as analytic and clinical response but requiring IFX dose/frequency adjustment or association with another drug. RESULTS Baseline CRP levels were higher in PNR compared with SR (26.2mg/L vs 9.6 mg/L, p=0.015) and RTA (26.2mg/L vs 7.6 mg/L, p=0.007). CRP levels greater than 15 mg/L at baseline predict PNR with 67% sensitivity and 65% specificity. Lower CRP levels at week 14 were more likely to predict SR relative to RTA (3.1mg/L vs 7.6 mg/L p=0.019) and PNR (3.1mg/L vs 9.1mg/L; p=0.013). CRP levels greater than 4.6 mg/L at week 14 predict PNR with 67% sensitivity and 62% specificity. A higher CRP delta between beginning of treatment and week 14 is more likely to predict SR relative to RTA (5.2mg/L vs 0.6 mg/L p=0.027). CONCLUSION CRP levels at week 14 were associated with SR in patients treated with IFX, independently of baseline CRP serum levels. High inflammatory burden at beginning of IFX treatment was correlated with a worse response.

[1]  M. Kamm,et al.  Infliximab for the treatment of fistulas in patients with Crohn'S disease. , 1999, Gastroenterology.

[2]  Paul Rutgeerts,et al.  C-Reactive Protein as a Marker for Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[3]  A. Petrie,et al.  Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis , 1982, European journal of clinical investigation.

[4]  G. D'Haens,et al.  Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease , 2013, Current medical research and opinion.

[5]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[6]  B J Oddens,et al.  C‐reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post‐hoc analysis from ACCENT I , 2012, Alimentary pharmacology & therapeutics.

[7]  S. Fais,et al.  The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. , 1988, Journal of clinical gastroenterology.

[8]  K. Van Steen,et al.  Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  G. Veres,et al.  Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[10]  M. Samsom,et al.  C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. , 2008, World journal of gastroenterology.

[11]  J. Jahnsen,et al.  C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study , 2008, Gut.

[12]  Honghui Zhou,et al.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.

[13]  A. Griffiths,et al.  Review and clinical perspectives for the use of infliximab in ulcerative colitis. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[14]  B. Scallon,et al.  Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. , 1995, Cytokine.

[15]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[16]  B F Warren,et al.  European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. , 2008, Journal of Crohn's & colitis.

[17]  D. Rubin,et al.  Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial , 2012, Inflammatory bowel diseases.

[18]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[19]  P. Rutgeerts,et al.  Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.

[20]  J. Woody,et al.  Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. , 1997, Advances in immunology.

[21]  S. Na,et al.  Biological Therapy for Inflammatory Bowel Disease in Children , 2012 .

[22]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[23]  S. Deventer,et al.  Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease , 2002, Gut.

[24]  Paul Rutgeerts,et al.  Biological therapies for inflammatory bowel diseases. , 2009, Gastroenterology.

[25]  I. Kushner,et al.  C-reactive protein and the acute-phase response. , 1990, Hospital practice.

[26]  G E Wild,et al.  Predicting relapse in Crohn’s disease: a biopsychosocial model , 2008, Gut.

[27]  P. Rutgeerts,et al.  The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[28]  M. Campieri,et al.  A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. , 1986, Gastroenterology.

[29]  R. Modigliani,et al.  A simple biological score for predicting low risk of short‐term relapse in Crohn's disease , 2006, Inflammatory bowel diseases.

[30]  Honghui Zhou,et al.  PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis , 2009 .

[31]  A. Oxman,et al.  Systematic review to determine whether participation in a trial influences outcome , 2005, BMJ : British Medical Journal.

[32]  B. Sands,et al.  Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[34]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[35]  J. Lewis,et al.  Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis , 2002, American Journal of Gastroenterology.

[36]  L. Peyrin-Biroulet,et al.  Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy , 2010, The American Journal of Gastroenterology.

[37]  Mark Feldman,et al.  Sleisenger and Fordtran's gastrointestinal and liver disease , 2012 .

[38]  J. Belaiche,et al.  Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.

[39]  J. Belaiche,et al.  A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .

[40]  D. Mould,et al.  Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies , 2010, BioDrugs.

[41]  A. Tall.  C-reactive protein reassessed. , 2004, The New England journal of medicine.

[42]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[43]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[44]  Problem solving in real time. , 1990, Hospital practice.

[45]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[46]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.